WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm3 and 80–150-cm3 Prostates

David Dan Nguyen, Neil Barber, Mo Bidair, Peter Gilling, Paul Anderson, Kevin C. Zorn, Gopal Badlani, Mitch Humphreys, Steven Kaplan, Ronald Kaufman, Alan So, Ryan Paterson, Larry Goldenberg, Dean Elterman, Mihir Desai, Jim Lingeman, Claus Roehrborn, Naeem Bhojani

Research output: Contribution to journalArticlepeer-review

Abstract

Comparing data from WATER and WATER II trials, we found that Aquablation is effective in patients with a prostate of 30–80 cm3 and patients with a prostate of 80–150 cm3 treated for lower urinary tract symptoms due to benign prostatic hyperplasia, with comparable outcomes in both groups. Functional outcome improvements are durable and retreatment rates are low at 2 yr of follow-up.

Original languageEnglish (US)
Pages (from-to)21-28
Number of pages8
JournalEuropean Urology Open Science
Volume25
DOIs
StatePublished - Mar 2021

Keywords

  • Aquablation
  • Benign prostatic hyperplasia
  • Robotics

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm<sup>3</sup> and 80–150-cm<sup>3</sup> Prostates'. Together they form a unique fingerprint.

Cite this